pharma.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549


FORM 8-K

CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act Of 1934
 

 
Date of Report (Date of earliest event reported)
August 24, 2009


THE PROCTER & GAMBLE COMPANY
(Exact name of registrant as specified in its charter)
Ohio
 
1-434
 
31-0411980
(State or other jurisdiction
of incorporation)
 
(Commission File Number)
 
(IRS Employer
Identification Number)

One Procter & Gamble Plaza, Cincinnati, Ohio
 
45202
(Address of principal executive offices)
 
Zip Code

(513) 983-1100
 
45202
(Registrant's telephone number, including area code)
 
Zip Code


o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))



ITEM 7.01    REGULATION FD DISCLOSURE
 

On August 24, 2009, The Procter & Gamble Company (“Company”) and Warner Chilcott plc (“Warner Chilcott”) issued a news release announcing that the companies have reached an agreement for the sale of P&G’s global pharmaceuticals business to Warner Chilcott.
 
The Company is furnishing this 8-K pursuant to Item 7.01, "Regulation FD Disclosure."
 
 
SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.
 
          THE PROCTER & GAMBLE COMPANY
 
 
                               BY:         /S/  E.J. WUNSCH                                                      
          E.J. Wunsch
        Assistant Secretary
        August 24, 2009
 
EXHIBITS
 
99.1
News Release by The Procter & Gamble Company and Warner Chilcott plc dated August 24, 2009.